Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
When administered, these medications work through several mechanisms: Slowing gastric emptying - Food remains in the stomach longer, which can contribute to feelings of fullness Reducing appetite signaling - The medications act on brain regions involved in hunger and satiety Improving insulin secretion - In response to food intake, insulin release becomes more efficient, which is why these medications were originally developed for diabetes Decreasing glucagon secretion - This hormone raises blood sugar, so reducing it helps with glucose control The two primary GLP-1 receptor agonists used for weight loss are: Semaglutide - FDA-approved for weight management under the brand name Wegovy (also sold as Ozempic for diabetes and Rybelsus as an oral diabetes medication)
A., Yamamah, G
Lymphatic vasculature in energy homeostasis and obesity
According to FDA labeling, injectable semaglutide offers some flexibility in dosing
The FDA classifies most compounded semaglutide and tirzepatide formulations as Category C medications, meaning animal reproduction studies have shown adverse effects, but controlled human data is absent
